文献速递脊柱关节炎

银屑病关节炎随机临床试验中患者特征及先进疗法疗效与安全性的性别差异:系统文献综述与Meta分析

Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis.
PubMed 文献 · Lancet Rheumatol · 2023-11-14

该系统综述与Meta分析检索至2022年6月10日的随机对照试验,纳入54项试验共22621例银屑病关节炎患者(女性11514例,男性11107例),比较男女患者接受先进疗法(含生物制剂和靶向合成药物)的疗效与安全性。男性基线 tender joint count、HAQ、疼痛及整体评估低于女性,而PASI和CRP高于女性;多数药物类别中男性ACR20、ACR50和MDA应答率高于女性,但JAK与TYK2抑制剂无性别差异。

要点

  • 54项试验中仅9项(17%)报告按性别分层的基线特征,18项(33%)报告按性别分层的疗效,2项(4%)报告按性别分层的安全性终点。
  • 男性基线 tender joint count 较女性低3.01(95%CI -3.83至-2.18),HAQ低0.28(-0.33至-0.24),疼痛评分低4.58(-6.86至-2.30)。
  • 男性PASI较女性高1.95(95%CI 0.78至3.11),CRP高2.57(0.40至4.74)。

核心结论

  • 银屑病关节炎患者的生物学性别影响其对先进疗法的应答,但效应因药物类别而异。
  • 选择性报告可能影响了这些结果。
  • 未来试验应按性别报告基线特征和终点结果。

研究设计与样本

  • 系统综述与Meta分析,检索Medline、Embase、Central数据库及会议摘要档案,从建库至2022年6月10日,纳入评估先进疗法治疗银屑病关节炎疗效的随机对照试验。
  • 共纳入54项试验,22621例参与者中女性11514例(50.9%),男性11107例(49.1%)。
  • 采用随机效应模型按药物类别计算男性 versus 女性患者ACR20、ACR50和MDA的合并效应。

主要发现

  • 仅9项(17%)试验报告按性别分层的基线特征,18项(33%)报告按性别分层的疗效,2项(4%)报告按性别分层的安全性终点。
  • 男性基线 tender joint count 较女性低3.01(95%CI -3.83至-2.18),HAQ评分低0.28(-0.33至-0.24),疼痛评分低4.58(-6.86至-2.30),患者整体评估低3.22(-5.27至-1.17),医生整体评估低1.34(-2.08至-0.08)。
  • 男性基线PASI评分较女性高1.95(95%CI 0.78至3.11),CRP浓度高2.57(0.40至4.74)。
  • ACR20应答率男性 versus 女性:IL-17抑制剂OR 1.70(95%CI 1.38-2.11),IL-23抑制剂OR 1.46(1.20-1.78),IL-12和IL-23抑制剂OR 2.67(1.39-5.09),TNF抑制剂OR 1.55(1.11-2.18),JAK与TYK2抑制剂OR 1.10(0.87-1.38)无差异。
  • ACR50应答率男性 versus 女性:TNF抑制剂OR 2.17(95%CI 1.62-2.90),IL-17抑制剂OR 1.93(1.56-2.38),IL-23抑制剂OR 1.71(1.25-2.34),IL-12和IL-23抑制剂OR 2.43(1.14-5.20),JAK与TYK2抑制剂OR 1.09(0.73-1.62)无差异。

关键数值与推荐

  • ACR20应答男性高于女性的药物类别:IL-17抑制剂OR 1.70(95%CI 1.38-2.11),IL-23抑制剂OR 1.46(1.20-1.78),IL-12和IL-23抑制剂OR 2.67(1.39-5.09),TNF抑制剂OR 1.55(1.11-2.18)。
  • ACR20应答无性别差异:JAK与TYK2抑制剂OR 1.10(95%CI 0.87-1.38)。
  • ACR50应答男性高于女性的药物类别:TNF抑制剂OR 2.17(95%CI 1.62-2.90),IL-17抑制剂OR 1.93(1.56-2.38),IL-23抑制剂OR 1.71(1.25-2.34),IL-12和IL-23抑制剂OR 2.43(1.14-5.20)。
  • ACR50应答无性别差异:JAK与TYK2抑制剂OR 1.09(95%CI 0.73-1.62)。
  • MDA达成男性高于女性的药物类别:IL-17抑制剂OR 1.99(95%CI 1.50-2.63),IL-23抑制剂OR 1.79(1.29-2.50),TNF抑制剂OR 2.62(1.54-4.44),JAK与TYK2抑制剂OR 1.77(1.15-2.73)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 选择性报告可能影响了这些结果。
  • 未来试验应按性别报告基线特征和终点结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sex-related differences in clinical manifestations and disease outcomes exist in psoriatic arthritis, however, there is limited information on sex-related differences in randomised controlled trials of psoriatic arthritis. We aimed to compare patient characteristics and efficacy and safety of advanced therapies (including biological and targeted synthetic therapies) between male and female patients with psoriatic arthritis participating in randomised controlled trials. METHODS: In this systematic review and meta-analysis, we searched Medline, Embase, and Central databases, and conference abstract archives, from their inception to June 10, 2022, for randomised controlled trials that assessed the efficacy of advanced therapies in psoriatic arthritis. Two reviewers extracted information on participants' characteristics and rates of American College of Rheumatology (ACR) 20 and ACR50 response and minimal disease activity (MDA) by sex. Random-effects models were used to calculate pooled effects of ACR20, ACR50, and MDA in male versus female patients by drug class. FINDINGS: We included 54 trials (11 514 [50·9%] of 22 621 participants were female and 11 107 [49·1%] were male). Sex-disaggregated results were reported in a minority of studies (nine [17%] of 54 reported baseline characteristics by sex, 18 [33%] reported efficacy by sex, and two [4%] reported safety endpoints by sex). At baseline, male patients had lower baseline tender joint count (mean difference -3·01 [95% CI -3·83 to -2·18], health assessment questionnaire scores (-0·28 [-0·33 to -0·24]), pain scores (-4·58 [-6·86 to -2·30]), patient global assessment (-3·22 [-5·27 to -1·17]), and physician global assessment (-1·34 [-2·08 to -0·08]) than did female patients. Male patients had higher baseline psoriasis area and severity index scores (mean difference 1·95 [95% CI 0·78 to 3·11]) and C-reactive protein concentrations (2·57 [0·40 to 4·74]) than did female patients. ACR20 response by sex varied across drug classes, with higher rates in males than females with interleukin (IL)-17 inhibitors (odds ratio [OR] 1·70 [95% CI 1·38-2·11]), IL-23 inhibitor (1·46 [1·20-1·78]), IL-12 and IL-23 inhibitor (2·67 [1·39-5·09]), and tumour necrosis factor (TNF) inhibitors (1·55 [1·11-2·18]), but no difference with JAK and TYK2 inhibitors (1·10 [0·87-1·38]). Similarly, ACR50 response rates were higher in male patients versus female patients in all drug classes, with exception of JAK and TYK2 inhibitors (TNF inhibitors, OR 2·17 [95% CI 1·62-2·90]; IL-17 inhibitors, 1·93 [1·56-2·38]; IL-23 inhibitor, 1·71 [1·25-2·34]; IL-12 and 23 inhibitor, 2·43 [1·14-5·20]; and JAK and TYK2 inhibitors, 1·09 [0·73-1·62]). Male patients were more likely to reach MDA with most drug classes, including IL-17 inhibitors (OR 1·99 [95% CI 1·50-2·63]), IL-23 inhibitors (1·79 [1·29-2·50]), TNF inhibitors (2·62 [1·54-4·44]), and JAK and TYK2 inhibitors (1·77 [1·15-2·73]). Risk of bias was low for most studies. INTERPRETATION: Biological sex of patients with psoriatic arthritis influences their response to advanced therapies, but the effect varies by drug class. Selective reporting might have influenced these results. Future trials should report baseline characteristics and endpoint results by sex. FUNDING: Canadian Rheumatology Association.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Eder L, Mylvaganam S, Pardo Pardo J, et al. Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis. Lancet Rheumatol. 2023. PMID: 38251562. doi:10.1016/S2665-9913(23)00264-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。